PMA synergistically enhances apicularen A-induced cytotoxicity by disrupting microtubule networks in HeLa cells

• Published in: BMC cancer Vol. 14; no. 1; p. 36
• Main Authors: Seo, Kang-Sik, Kim, Jong-Seok, Park, Ji-Hoon, Song, Kyoung-Sub, Yun, Eun-Jin, Park, Jong-Il, Kweon, Gi Ryang, Yoon, Wan-Hee, Lim, Kyu, Hwang, Byung-Doo
• Format: Journal Article
• Language: English
• Published: England BioMed Central 22.01.2014; BioMed Central Ltd
• Subjects: Antineoplastic Combined Chemotherapy Protocols - pharmacology; Apoptosis; Apoptosis - drug effects; Bridged Bicyclo Compounds, Heterocyclic - pharmacology; Caspase 3 - metabolism; Cell cycle; Cell Cycle Checkpoints; Cell Survival - drug effects; Drug Synergism; Female; HeLa Cells; Humans; Kinases; Medical research; Microtubules - drug effects; Microtubules - genetics; Microtubules - metabolism; Microtubules - pathology; Protein Kinase C-alpha - antagonists & inhibitors; Protein Kinase C-alpha - genetics; Protein Kinase C-alpha - metabolism; Protein Kinase Inhibitors - pharmacology; RNA Interference; Tetradecanoylphorbol Acetate - pharmacology; Time Factors; Transfection; Tubulin - genetics; Tubulin - metabolism; Tubulin Modulators - pharmacology; Uterine Cervical Neoplasms - genetics; Uterine Cervical Neoplasms - metabolism; Uterine Cervical Neoplasms - pathology

Combination therapy is key to improving cancer treatment efficacy. Phorbol 12-myristate 13-acetate (PMA), a well-known PKC activator, increases the cytotoxicity of several anticancer drugs. Apicularen A induces cytotoxicity in tumor cells through disrupting microtubule networks by tubulin down-regul...